Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$3.80 USD

3.80
2,732,199

-0.07 (-1.81%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FATE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Fate Therapeutics, Inc. [FATE]

Reports for Purchase

Showing records 261 - 280 ( 425 total )

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

12/03/2018

Daily Note

Pages: 3

Presents Phase 1 Data for ProTmune Graft in GvHD Prophylaxis at ASH 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

11/30/2018

Daily Note

Pages: 3

Fate Therapeutics Receives IND Clearance from FDA for FT500, Off-the-Shelf NK Cell Product

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

11/30/2018

Industry Report

Pages: 6

Correction: The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

11/14/2018

Industry Report

Pages: 13

SITC 2018 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

11/12/2018

Company Report

Pages: 8

Fate Therapeutics Presents Updates for Programs at SITC 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

11/05/2018

Industry Report

Pages: 14

UPDATED: ASH 2018 Abstract Roundup and Schedule for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

11/05/2018

Industry Report

Pages: 14

CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

11/05/2018

Industry Report

Pages: 12

ASH 2018 Abstract Roundup and Schedule for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

11/02/2018

Company Report

Pages: 7

3Q18 Financials; Looking Ahead to SITC and ASH

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

11/02/2018

Company Report

Pages: 8

FATE Therapeutics 3Q18 Results; Platform Progress Heading into SITC 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

09/19/2018

Company Report

Pages: 7

ONO Collaboration Offers Path to Asia Markets

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

09/19/2018

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

09/18/2018

Company Report

Pages: 8

FATE Therapeutics Announces Collaboration for Off-the-Shelf CAR-T Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

09/07/2018

Company Report

Pages: 4

We are dropping coverage of FATE shares to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

08/07/2018

Company Report

Pages: 8

2Q18 Results: Pipeline Continues to Progress, Looking to SITC and ASH for Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

08/07/2018

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

08/07/2018

Company Report

Pages: 7

2Q18 Financials; Looking Ahead to a Catalyst-Rich 2H18

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

07/24/2018

Company Report

Pages: 7

Model Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

07/20/2018

Industry Report

Pages: 8

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

07/13/2018

Industry Report

Pages: 8

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party